Athira Pharma’s stock price fell 81% as its lead fosgonimeton treatment for Alzheimer’s disease failed its phase II/III LIFT-AD clinical trial. The drug did not meet the trial’s primary or key secondary endpoints. However, chief medical officer Javier San Martin said Athira planned to continue developing fosgonimeton, citing preliminary results from various subgroups.
Nurses file complaints over patient safety at Tenet hospitals
Nurses from Framingham Union Hospital in Massachusetts have filed complaints with state and federal agencies, alleging patient safety is being jeopardised due to insufficient staffing,
